NCT07042321 Risk Factors for Microvascular Obstruction Post-Emergency PCI in AMI Patients
| NCT ID | NCT07042321 |
| Status | Recruiting |
| Phase | — |
| Sponsor | The Third Xiangya Hospital of Central South University |
| Condition | Acute Myocardial Infarction (AMI) |
| Study Type | OBSERVATIONAL |
| Enrollment | 300 participants |
| Start Date | 2024-06-01 |
| Primary Completion | 2025-08-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 300 participants in total. It began in 2024-06-01 with a primary completion date of 2025-08-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this prospective cohort study is to investigate the relationship between the TyG index and early identification of MVO in AMI patients undergoing emergency PCI and CMR imaging. The study will enroll approximately 300 AMI patients treated at Xiangya Third Hospital of Central South University from June 2024 to August 2025. The main questions it aims to answer are: * How does the TyG index correlate with the early detection of MVO? * What differences in cardiovascular adverse events during hospitalization exist between groups with varying TyG index levels? Participants will undergo emergency PCI and CMR imaging within 3-7 days post-procedure. Data collected will include demographic characteristics, clinical history, coronary angiography data, laboratory test indicators (especially metabolic markers such as blood glucose and lipids), IVUS-related plaque information, and CMR results.
Eligibility Criteria
Inclusion Criteria: * Age ≥ 18 years. * STEMI symptom onset time \< 12 hours. * STEMI symptom onset time 12-48 hours, with ongoing ischemic symptoms, hemodynamic instability, or life-threatening ventricular arrhythmias. * Very high-risk NSTEMI; undergoing emergency PCI treatment. * Voluntary signed informed consent form. Exclusion Criteria: * Non-obstructive acute myocardial infarction. * Severe chronic kidney disease (defined as estimated glomerular filtration rate \<20 mL/min per 1.73 m²). * Pregnant women or those planning to become pregnant. * Failure of emergency PCI. * Unclear CMR images
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07042321 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Acute Myocardial Infarction (AMI). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07042321 currently recruiting?
Yes, NCT07042321 is actively recruiting participants. Contact the research team at zhucan1021@163.com for enrollment information.
Where is the NCT07042321 trial being conducted?
This trial is being conducted at Changsha, China.
Who is sponsoring the NCT07042321 clinical trial?
NCT07042321 is sponsored by The Third Xiangya Hospital of Central South University. The trial plans to enroll 300 participants.